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Abstract
Malignant cancers that lead to fatal outcomes for
patients may remain dormant for very long peri-
ods of time. Although individual mechanisms such
as cellular dormancy, angiogenic dormancy and im-
munosurveillance have been proposed, a compre-
hensive understanding of cancer dormancy and the
“switch” from a dormant to a proliferative state
still needs to be strengthened from both a basic
and clinical point of view. Computational mod-
eling enables one to explore a variety of scenar-
ios for possible but realistic microscopic dormancy
mechanisms and their predicted outcomes. The aim
of this paper is to devise such a predictive com-
putational model of dormancy with an emergent
“switch” behavior. Specifically, we generalize a pre-
vious cellular automaton (CA) model for prolifera-
tive growth of solid tumor that now incorporates
a variety of cell-level tumor-host interactions and
different mechanisms for tumor dormancy, for ex-
ample the effects of the immune system. Our new
CA rules induce a natural “competition” between
the tumor and tumor suppression factors in the mi-
croenvironment. This competition either results in
a “stalemate” for a period of time in which the tu-
mor either eventually wins (spontaneously emerges)
or is eradicated; or it leads to a situation in which
the tumor is eradicated before such a “stalemate”
could ever develop. We also predict that if the num-
2ber of actively dividing cells within the proliferative
rim of the tumor reaches a critical, yet low level, the
dormant tumor has a high probability to resume
rapid growth. Our findings may shed light on the
fundamental understanding of cancer dormancy.
Introduction
Cancer dormancy, the phenomena that the tumor’s
volume or the number of tumor cells stays at a very
low level for a certain period of time before the tu-
mor begins to grow rapidly, has been an outstanding
issue in cancer research for many years [1, 2]. Cur-
rently, the mechanisms responsible for the “switch”
from a dormant state to a rapid growth state for
different tumors are not well understood, although
it is well known that such a “switch” in secondary
metastatic tumors can be triggered by the removal
of the primary tumor. This could eventually lead
to failure of tumor treatment and fatal outcomes
for the patient. Therefore, a comprehensive under-
standing of the “switch” from a dormant to a pro-
liferative state is crucial to our fundamental under-
standing of cancer progression and recurrence and
might lead to the development of novel treatments
for cancer.
Dormancy has been observed in many types of
cancer. This includes tumor dormancy before any
metastases take place and the latency of cancer re-
currence after therapy. In some cases of pancreatic
cancer, the tumor can remain in a benign dormant
state for about 20 years [3]. During this time, it is
undetectable by conventional clinical methods, and
it is only afterwards that the tumor becomes highly
malignant and grows aggressively with highly fatal
outcomes after about a year. In the cases of breast
and prostate cancer, it is reported that 20%-45%
of patients will relapse years or decades later after
the resection of the primary tumor [4–6]. In addi-
tion, recurrence has been observed in brain tumors,
which indicates the existence of a large number of
micrometastases that are dormant in the presence
of the primary tumor [7, 8].
Extensive studies over years have revealed three
major cancer dormancy mechanisms: cellular dor-
mancy, angiogenic dormancy and immunosurveil-
lance [1,2]. On the cellular level, a tumor cell could
be arrested at a certain stage of the cell cycle and
unable to complete the cell division process suc-
cessfully, resulting in a dormant solitary cell [9–11].
On the cell population level, when the population
does not gain enough ability to recruit blood vessels
and promote neovascularization, the tumor cannot
obtain sufficient nutrients necessary for its prolif-
eration and as a result, angiogenic dormancy oc-
curs [12, 13]. On other hand, immunosurveillance
operates when the immune system suppresses the
proliferation of tumor cell population and leads to
the dormancy of the tumor [14–18]. Figure 1(a)
shows an image of tumor tissue surrounded by im-
3mune cells. Figure 1(b) compares the morphology
and vascular structure of dormant and fast-growing
tumors.
A comprehensive understanding of cancer dor-
mancy and the “switch” from a dormant to a pro-
liferative state still needs to be strengthened. This
is mainly due to the fact that efficient and accu-
rate experimental or clinical approaches to track
the states of individual cells in a dormant tumor
in vivo throughout the entire dormancy period are
still under development [19–21].
Given the current need for further understand-
ing of dormancy, computational modeling provides
a powerful means to probe various scenarios for
the underlying mechanisms. Specifically, model-
ing enables one to probe a variety of different dor-
mancy scenarios by examining different combina-
tions of mechanisms in order to see which ones
provide possible explanations for experimental and
clinical observations. Over the past few decades,
computational modeling has played an important
role in the study of the progression of solid tu-
mors [22]; a variety of models based on different
mathematical schemes have been developed, includ-
ing continuum models [23–26], discrete cell mod-
els [27, 28] and hybrid models [29, 30]. Various
models have been used to investigate cancer dor-
mancy caused by cancer-immune interactions and
other mechanisms, including ordinary differential
equation-based models [31, 32], stochastic differen-
tial equation-based models [33], models based on
kinetic theory for active particles [34–36], and cel-
lular automaton models [37]. However, the afore-
mentioned studies neither explicitly demonstrated
how the dynamic process of active proliferation af-
ter a certain period of dormancy emerges from vari-
ous microscopic mechanisms nor showed the associ-
ated growth dynamics of the “switch” phenomenon.
Therefore, predictive computational models that in-
corporate cellular-level microscopic mechanisms are
needed to address these important issues.
In this paper, we generalize a two-dimensional
(2D) cellular automaton (CA) model that we have
devised to study proliferative growth of avascular
solid tumors [38–42] in order to investigate tumor
dormancy. Our goal is to formulate a dynamical
model in which the “switch” to a proliferative state
spontaneously emerges by incorporating additional
interactions between the tumor and the microen-
vironment, for example the effects of immune sys-
tem, which were not included in our previous CA
model. The new rules of our CA model induce a
“competition” between the tumor’s propensity to
proliferate and the microenvironmental factors that
suppress its growth. In our model, a fraction of the
dormant cells undergo phenotypic transformations
triggered by intracellular factors or external stim-
ulus and acquire the ability to actively proliferate.
Subsequently, those microenvironmental factors act
to suppress the growth of these transformed tumor
4cells either by killing some of these cells or turning
these actively dividing proliferative cells back into
dormant cells.
The “competition” between the tumor and the
microenvironmental suppression factors either re-
sults in a “stalemate” for a period of time in which
the tumor either eventually wins (spontaneously
emerges) or is eradicated; or it leads to a situation in
which the tumor is eradicated before such a “stale-
mate” could ever develop. Since we are mainly in-
terested in the situations in which tumor growth
involves a period of dormancy, we will henceforth
focus on those situations in which a “stalemate”
between the tumor and the microenvironmental
suppression factors develops. Our model demon-
strates that a variety of parameters characterizing
the tumor-host interactions may greatly alter the
growth dynamics of the tumor. These parameters
include the rate of phenotypic transformation, by
which the tumor cells gain the ability to proliferate
against those suppression factors, the suppression
rate imposed by suppression factors on individual
tumor cells, and the mechanical rigidity of the mi-
croenvironment. The growth dynamics influenced
by these parameters include the existence of a dor-
mant period in tumor’s growth, the length of the
dormant period (if there exists one) and the exis-
tence of a sudden “switch” to a highly proliferative
state. We also demonstrate that if the number of
actively dividing cells within the proliferative rim
reaches a critical, yet low level, the tumor has a
high probability to begin rapid proliferation. While
we study a 2D CA model for simplicity in this pa-
per, our model can be easily generalized to three
dimensions (3D).
Figure 1. (Color online) (a) Fluorescence
micrograph of a breast tumor stained to visualize
carcinoma cells (phospho-p53, green) surrounded
by macrophages (CD11b, red). Nuclei appear blue
(DAPI). Image courtesy of Michael Graham
Espey, PhD, National Cancer Institute, NIH
(private communication). (b) Representative
pictures of dormant and fast-growing tumors and
their vascular structure. Reprinted from Cancer
Letters, 294, Almog N, Molecular mechanisms
underlying tumor dormancy, 139–146, Copyright
(2010), with permission from Elsevier.
Materials and Methods
We divide the two-dimensional square simulation
box into different polygonal units (i.e., automaton
cells). Our model is coarse-grained, allowing us
to grow the tumor from a very small size with a
cross section of roughly 1000 real cells through to
a fully developed tumor with a cross section con-
sisting of 2.0× 106 cells. Specifically, the innermost
automaton cells represent roughly 100 real tumor
5cells or or a region of host microenvironment of
similar size, while the outermost automaton cells
represent roughly 104 real tumor cells or a region of
host microenvironment of similar size. To generate
the automaton cells in the simulation box, we first
fill the simulation box with non-overlapping circular
disks (or spheres in 3D) using random-sequential-
addition packing method [43] until there is no void
space left for additional circular disks (or spheres in
3D). Periodic boundary conditions are used for gen-
erating the packing. Then we divide the simulation
box into polygons (or polyhedra in 3D), each poly-
gon (or polyhedron in 3D) associated with a par-
ticle center, such that any point within a polygon
(or polyhedron in 3D) [i.e., a Voronoi polygon (or
polyhedron in 3D)] is closer to its associated particle
center than to any other particle centers. The re-
sulting Voronoi polygons (or polyhedra in 3D) are
referred to as automaton cells. In this paper, we
focus on the two-dimensional case, but our model
should be readily generalized to three dimensions.
The microenvironment surrounding a tumor is
mainly composed of stroma cells and extracellular
matrix (ECM). In the current model, we explicitly
take into account the effects of the ECM macro-
molecule density, ECM degradation by the prolif-
erative cells, and the pressure built up due to the
ECM deformation by tumor growth. The effects of
the stroma cells are not explicitly considered in our
current model. Henceforth, we will refer to the re-
gions of microenvironment as ECM-associated cells
for simplicity. In addition, we consider the interac-
tions between the tumor and the various suppres-
sion factors in the microenvironment, for example
the immune system. Since we consider develop-
ment of primary tumor or local recurrences of mi-
crometastases under microenvironmental suppres-
sion, invasive tumor growth is not a mechanism rel-
evant for our purposes and hence is not included in
our dormancy model.
In our model of noninvasive proliferative tumor
growth, tumor cells can be in one of the three pos-
sible states: proliferative, quiescent or necrotic, de-
pending on their nutrient supply. Proliferative cells
are tumor cells that have enough nutrients and pos-
sess the ability to divide. Quiescent (or arrested)
cells are tumor cells that are alive, but do not
have enough nutrient supply to support cell divi-
sion. Quiescent cells can eventually become inert,
necrotic (dead) cells due to an insufficient nutrient
supply. In this paper, we focus on avascular tumor
growth and assume that there is no explicit angio-
genesis during the growth process (although this
assumption can be relaxed). The nutrients avail-
able to tumor cells are those that diffuse into the
tumor region through tumor edge. As the tumor
grows, the amount of nutrient supply, which is pro-
portional to the perimeter of the tumor interface
(or surface area of the tumor interface in 3D), can-
not meet the needs of all of the tumor cells. As a
6result, quiescent and necrotic regions emerge near
the center of the tumor. The state of a tumor cell is
determined by its distance to the tumor edge (i.e.,
the source of nutrients). We assume that prolifer-
ative cells more than δp away from the tumor edge
become quiescent and quiescent cells more than δn
away from the tumor edge become necrotic (see de-
tails below).
In this section, we will introduce our CA dor-
mancy model, which modifies our previous basic
CA models of tumor growth [41,42,44] by introduc-
ing several additional parameters to incorporate the
interactions between tumor cells and the microen-
vironmental suppression factors. This dynamical
model is capable of producing situations in which
a “switch” from a dormant state to a proliferative
state spontaneously emerges.
Noninvasive proliferative tumor
growth
We now specify the cellular automaton rules used
in our model for noninvasive proliferative tumor
growth. Each ECM-associated automaton cell is
assigned a specific density ρECM, representing the
density of the ECM molecules within the automa-
ton cell. If a proliferative cell divides, its daughter
cell occupies a nearby ECM-associated cell. The
daughter cell pushes away or degrades the ECM
within the ECM-associated cell it occupies. Ini-
tially, a tumor is introduced by designating several
automaton cells at the center of the growth permit-
ting region as proliferative tumor cells. Then time
is discretized into units, with each time step repre-
senting one day. At each time step, the tumor grows
according to the following cellular automaton rules.
• Quiescent cells more than a certain distance
δn from the tumor’s edge are turned necrotic.
The tumor’s edge, which is assumed to be
the source of nutrients, consists of all ECM-
associated cells that border the tumor. The
critical distance δn for quiescent cells to turn
necrotic is computed as follows:
δn = aL
(d−1)/d
t , (1)
where a is the necrotic thickness controlled
by nutritional needs, d is the Euclidean spa-
tial dimension and Lt is the distance between
the geometric centroid xc of the tumor (i.e.,
xc =
∑N
i xi/N , where N is the total number
of cells in the tumor) and the tumor edge cell
that is closest to the quiescent cell under con-
sideration.
• Proliferative cells more than a certain distance
δp from the tumor’s edge are turned quiescent.
The critical distance δp is given by
δp = bL
(d−1)/d
t , (2)
where b is the proliferative thickness controlled
7by nutritional needs, d is the spatial dimension
and Lt is the distance between the geometric
tumor centroid xc and the tumor edge cell that
is closest to the proliferative cell under consid-
eration.
• The probability of division for a proliferative
cell used in our model is
pdiv = p0[1− ρECM − ω
∗(ξ − 1) + ξ
ℓ
w
]. (3)
where p0 = 0.192 is the base probability of di-
vision linked to cell-doubling time, ρECM is the
local ECM density, ω∗ = 2ρ0
ECM
is a parame-
ter taking into account the effect of pressure,
ξ = ρECM/ρ
0
ECM
is the ratio of current average
ECM density over the initial density, and ℓ and
w are, respectively, the length and width of lo-
cal protrusion tips.
Interactions between the tumor and
the microenvironmental suppression
factors
Here, we specify the additional interaction rules be-
tween the tumor and the microenvironmental sup-
pression factors beyond the aforementioned ones for
noninvasive proliferative growth, which were not in-
cluded in our previous CA models. We assume that
there are two possible states of proliferative cells,
dormant or actively dividing, depending on their
interactions with the microenvironmental suppres-
sion factors.
• Initially, we assume that all proliferative cells
are kept in dormant states by the microen-
vironmental suppression factors, which means
that they are not able to divide.
• At each day, beyond the aforementioned CA
rules for proliferative noninvasive growth, each
dormant proliferative cell has a certain proba-
bility γ to change in their phenotypes due to
intracellular factors or external stimulus. The
cell with phenotype change gains different de-
grees of resistance to the suppression factors
in the microenvironment, depending on the
specific phenotype change the cell undergoes.
For example, mutated leukaemic cells in acute
myeloid leukaemia acquire resistance to cyto-
toxic T lymphocytes-mediated cell lysis, whose
degree is related to the level of the cell’s ex-
pression of B7-H1 or B7.1 [45]. For simplicity,
we divide the phenotypic changes into two dif-
ferent types: weak changes and strong changes
with respect to their resistance to the suppres-
sion factors in the microenvironment (i.e. their
ability to actively proliferate). Henceforth,
we will refer to these phenotypic changes as
“transformations” and the cells that undergo
these changes as “transformed” cells for sim-
plicity. Strong-type “transformed” cells gain a
8larger competition advantage and thus have a
greater ability to divide actively. The quanti-
ties xW and xS are the fractions of weak-type
“transformations” and strong-type “transfor-
mations”. Henceforth, we set xW 0.99 and xS
0.01.
• At each subsequent day, the microenviron-
mental suppression factors will counteract
the weak-type “transformed” and strong-type
“transformed” cells with probabilities αW and
αS . The suppression factors in the microenvi-
ronment will either kill the “transformed” cells
or turn them back into dormant cells [14, 15].
• When the number of tumor cells reaches a
certain threshold NT , strong reactions of the
microenvironmental factors are triggered and
those factors start to kill the “transformed”
cells. The parameter NT is introduced to en-
sure that the tumor is not completely removed
by the microenvironmental suppression factors.
Note that the particular choice of NT barely
has any effect on the simulation results within
a relatively wide range of NT values. In this
work NT is set to be 50, a sufficiently small
value that leads to biophysically realistic out-
comes. As the tumor grows, the microenviron-
mental factors are weakened by the tumor, re-
sulting in weaker suppression of the tumor cells
[46,47]. Therefore, when the microenvironmen-
tal factors counteract the “transformed” cells,
the fraction of the cells that are killed can be
coupled with the growth rate of the tumor by
k = k0(1−
1
△rC
dA
dt
). (4)
where k0 is a constant characterizing the
strength of the suppression factors in the mi-
croenvironment, dA/dt is the daily area change
of the tumor (i.e. the growth rate of the tu-
mor), and △rC is the critical value of the tu-
mor’s growth rate. In this work, △rC is cho-
sen as half of the tumor’s maximum growth
rate under suppression, but our numerical tests
have revealed that the simulation results are in-
sensitive to the choice of △rC as long as △rC
is smaller than the tumor’s maximum growth
rate. When the growth rate of the tumor
reaches this critical value, the suppression fac-
tors become too weak to kill any actively di-
viding tumor cells and k is set to be 0 [46, 47].
• Due to the “competition” between the tumor
and the suppression factors in the microenvi-
ronment, the ratio of the number of actively di-
viding proliferative cells over the total number
of proliferative cells nproacti/n
pro changes with
time. The larger is this ratio nproacti/n
pro, the
larger is the amount of nutrients the tumor tis-
sue consumes. As a result, the nutrient concen-
tration around the tumor depends on the ratio
9nproacti/n
pro. Therefore, we make the necrotic
thickness a and proliferative thickness b func-
tions of nproacti/n
pro:
a = a0[q − (q − 1.0)
nproacti
npro
]. (5)
b = b0[s− (s− 1.0)
nproacti
npro
]. (6)
where a0 = 0.58 mm
1/2 and b0 = 0.30 mm
1/2
are base necrotic thickness and base prolif-
erative thickness respectively, q = 1.6, s =
2.0 are parameters determining the ranges of
necrotic thickness and proliferative thickness as
nproacti/n
pro changes.
The aforementioned additional parameters asso-
ciated with the new rules that we employ for dor-
mancy (beyond the ones for noninvasive prolifer-
ative growth) are summarized in Table 1. These
parameters are sufficient to formulate a model in
which the transition from “dormant” to prolifera-
tive state emerges spontaneously. Note that unlike
other parameters listed in Table 1, the two criti-
cal threshold parameters themselves do not incor-
porate any additional CA rules. Instead, the critical
threshold parameters determine when the microen-
vironmental suppression factors are able to kill the
proliferative cells. Also, it is noteworthy that we
map the complicated tumor-host interactions onto
a number of “effective” parameters. The values of
these parameters could differ for different tumors in
Table 1. Parameters characterizing the
interactions between tumor suppression
factors and tumor cells in the CA dormancy
model. Note that the two “critical
threshold” parameters themselves do not
incorporate any additional CA rules.
Tumor growth parameters
γ
Probability of phenotypic change for a
dormant proliferative cell to acquire the
dividing ability
xW Fraction of weak-type transformations
xS Fraction of strong-type transformations
Microenvironmental suppression parameters
αW
Probability that suppression factors
counteract the weak-type transformed
cell at each day
αS
Probability that suppression factors
counteract the strong-type transformed
cell at each day
k
Fraction of “transformed” cells killed
when suppression factors counteract
the “transformed” cells (time depen-
dent)
Critical threshold values
NT
Critical value of proliferative tumor cell
number, beyond which suppression of
tumor growth is triggered
△rC
Critical value of tumor growth rate, be-
yond which the suppression factors are
unable to kill the “transformed” cells
different microenvironments. It is noteworthy that
currently due to a lack of detailed in-vivo or in-
vitro data for the growth dynamics of a dormant
tumor, we are not able to determine the values of
the parameters in our model for a specific real sys-
tem. Instead, we have done a full parametric study
to probe different outcomes corresponding to dif-
10
ferent parameter values in the subsequent sections.
However, once we obtain the statistics of a dormant
tumor as a function of time from the initiation of
the tumor, we should be able to extract the param-
eter values for the tumor by fitting the statistics.
At this stage, the extracted parameter values could
be applied to other tumors of similar type.
Noninvasive proliferative tumor
growth under suppression
Here, we specify how the additional interaction
rules are coupled together with the original CA
rules for noninvasive proliferative tumor growth, re-
sulting in noninvasive proliferative tumor growth
under suppression.
• As mentioned above, proliferative cells in the
dormant state do not divide. Only proliferative
cells in actively dividing states actually prolif-
erate.
• At each day, each dormant proliferate cell is
checked to see if it enters the active state ac-
cording to the interaction rules. Once it begins
to actively divide, it proliferates according to
the CA rules for proliferative tumor growth.
• At each day, each active proliferative cell is
checked to see if it is killed or turned back into
dormant cell according to the interaction rules.
• Quiescent cells and necrotic cells act accord-
ing to CA rules for proliferative tumor growth.
However, the values of parameters a and b de-
termining the transitions from necrotic cells to
quiescent cells and from proliferative cells to
quiescent cells respectively are influenced by
interaction rules, as mentioned above.
Note that our CA dormancy model should be
readily generalized to angiogenic dormancy by ex-
plicitly considering the angiogenic process and vas-
cular tumor growth. This is beyond the scope of
this work and will be addressed in future work.
Results
In this section, we apply our CA model and show
that it produces a dormancy period of the tumor
that can lead to a subsequent emergent “switch”
behavior to a proliferative state. A homogeneous
distribution of ECM density is used for simplicity
[41]. A circular growth permitting region containing
∼ 2× 104 automaton cells is employed. Simulating
the growth of a 2D tumor from several cells (rep-
resenting roughly 1000 real cells) to a macroscopic-
size tumor (a cross section of 5 cm2 consisting of
∼ 2× 106 real cells) with a period of dormancy up
to a person’s life (∼ 80 years) generally takes no
more than a few minutes on a standard Dell Work-
station (Precision T3400).
Initially, a few automaton cells at the center of
the growth-permitting region are designated as pro-
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liferative cells. Then the initial tumor is allowed
to grow according to our CA model incorporating
the additional interaction rules between the tumor
and the suppression factors in the microenviron-
ment. Certain geometrical characteristics of the tu-
mor (e.g., tumor area, areas of different tumor cell
populations) and its morphology (e.g., the geomet-
rical positions of the tumor cells) are collected every
Tc days. We set γ = 0.005, αW = 0.75, αS = 0.15,
k0 = 0.8 and use these parameter values throughout
this paper, except where otherwise stated.
Statistics of tumor growth
Here we consider the growth of a proliferative tumor
in a confined space with ρ¯ECM = 0.30. As shown
in Figure 2(a), with the interactions between the
tumor and the microenvironmental suppression fac-
tors incorporated, there exists a period of dormancy
in the tumor’s growth. Specifically, for the initial
approximate 900 days, the tumor stays in a dor-
mant state. Suddenly at approximately day 900,
the tumor switches its behavior and begins rapid
proliferation. The virtual patient would die 100
days after this critical point in time. Figure 2(b)
shows the areas A of different populations normal-
ized by the area of the growth-permitting area A0.
For purposes of comparison, Figure 2(c) and Fig-
ure 2(d) show the statistics of the tumor growth
without the suppression of microenvironmental fac-
tors. Moreover, by comparing Figure 2(a) and Fig-
ure 2(c), it is seen that the interactions between the
tumor and the microenvironmental suppression fac-
tors lead to the existence of a dormancy period and
a subsequent emergent “switch” behavior of the tu-
mor from a dormant state to a proliferative state.
Also, from the comparison of Figure 2(b) and Fig-
ure 2(d), one can see that the additional interaction
rules alter the fractions of necrotic cell population
and proliferative cell population within the tumor.
When suppression of the tumor growth is present,
the necrotic region decreases and the proliferative
region increases relatively; the area of the quiescent
region remains almost unchanged.
Figure 3 shows snapshots of the simulated 2D tu-
mor. It can be clearly seen that the tumor develops
a highly aspherical morphology due to the interac-
tions between the tumor and the microenvironmen-
tal factors. Figure 3 also demonstrates that the
tumor hardly grows during the period of dormancy,
but once the “switch” occurs, the tumor expands
very rapidly. Henceforth, we will use the “CA dor-
mancy model” to investigate the effects of the var-
ious parameters characterizing the tumor-host in-
teractions on the growth dynamics of the tumor.
These parameters include the rate of phenotypic
transformation, by which the tumor cells gain the
ability to proliferate against those suppression fac-
tors, the suppression rate imposed by suppression
factors on individual tumor cells, and the mechani-
cal rigidity of the microenvironment.
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Figure 2. (Color online) Upper panel: statistics
of a simulated noninvasive tumor growing in the
ECM with ρ¯ECM = 0.3 and microenvironmental
suppression factors, as predicted by the “CA
dormancy model”. (a) Tumor area AT normalized
by the area A0 of the growth permitting region.
(b) Areas of different cell populations normalized
by the area A0 of the growth permitting region.
Lower panel: statistics of a simulated noninvasive
tumor growing in the ECM with ρ¯ECM = 0.3
without suppression. (c) Tumor area AT
normalized by the area A0 of the growth
permitting region. (d) Areas of different cell
populations normalized by the area A0 of the
growth permitting region.
Suppression rate vs transformation
rate
Here we investigate growth dynamics of the tumor
under different suppression rates α and phenotypic
transformation rates γ. The suppression rate α is
defined as the following weighted average:
α = αW · xW + αS · xS . (7)
Figure 3. (Color online) Snapshots of a
simulated noninvasive tumor growing in the ECM
with ρ¯ECM = 0.3 on different days given by the CA
dormancy model. Upper panel: Dormancy period.
Lower panel: Regrowth period.
where xW = 0.99 and xS = 0.01 are the frac-
tions of weak-type “transformations” and strong-
type “transformations”, and αW and αS are the
suppression rates of the weak-type “transformed”
cells and strong-type “transformed” cells by the
microenvironmental factors. It is found that in-
creasing α and decreasing γ generally increases
the length of the dormancy period and delays the
“switch” from a dormant state to a proliferative
state, as demonstrated in Figure 4(a). Within some
regimes of α and γ, the tumor could lie dormant for
a period equal to or longer than a person’s life (∼ 80
years).
Based on our simulation results, we construct a
“phase diagram” to characterize the tumor’s growth
dynamics in terms of α and γ, as shown in Figure
4(b). There are two regions in this phase diagram:
proliferative and dormant regions. By “prolifera-
tive”, we mean that the tumor resumes rapid pro-
liferation after a period of dormancy and the length
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of the dormancy period is less than a virtual pa-
tient’s life; by “dormant”, we mean that the tumor
remains in a dormant state during the whole life
of a person and undetected by conventional clinical
methods (usually clinicians call such tumors “be-
nign” [48–50]). The solid line separates the two re-
gions, and crossing this boundary line is associated
with a “phase transition”.
Figure 4. (Color online) (a) The “critical” point
at which the noninvasive tumor growing in the
ECM with ρ¯ECM = 0.3 switches from a dormant
state to a proliferative state as functions of α and
γ. (b) A schematic phase diagram that
characterizes the growth dynamics of a
noninvasive tumor growing in the ECM with
ρ¯ECM = 0.3 under different α and γ.
Rigidity of the microenvironment
Various mechanical cues in the microenvironment
could influence the growth dynamics of the tumor
[51]. Here we only consider the effects of the ECM
macromolecule density, ECM degradation by the
proliferative cells, and the pressure built up due to
the ECM deformation by tumor growth. As shown
in Figure 5, when ECM rigidity increases, the time
at which the switch occurs gets delayed significantly
and the final size of the tumor when it plateaus ap-
preciably decreases. For example, with all the other
parameters fixed, when the tumor grows in a soft
ECM with ρ¯ECM = 0.15, the “switch” point occurs
approximately on day 250. This is to be contrasted
with growth in a rigid ECM with ρ¯ECM = 0.45 where
the dormancy period could last for 2,000 days before
a “switch” to a proliferative state occurs. Also, the
plateau size of the tumor growing in a soft ECM
with ρ¯ECM = 0.15 is five times as large as that of
one growing in a rigid ECM with ρ¯ECM = 0.45. In
other words, when the tumor grows in a harsher mi-
croenvironment, it’s harder for the tumor to break
out of a dormant state and potential proliferative
growth is largely suppressed. Note that the rigid-
ity of the microenvironment could also affect tu-
mor growth via various intracellular signaling pro-
cesses [51]. Those mechanotransduction effects will
be incorporated into our CA dormancy model in fu-
ture work, which could result in different scenarios
from those reported here [51].
Strength of the suppression factors
Here we investigate how tumor growth dynamics
changes with the strength of the microenvironmen-
tal suppression factors. As shown in Figure 6, in-
creasing the fraction of actively dividing tumor cells
that are killed [i.e., increasing k0 in the equation
(4)] when the microenvironmental suppression fac-
tors (which we recall could either kill the “trans-
14
Figure 5. (Color online) Simulated tumor area
AT normalized by the area A0 of the growth
permitting region of a noninvasive tumor growing
in the ECM with different ρ¯ECM.
formed” cells or turn them back into dormant cells)
delays the “switch” point from a dormant state to
a rapid proliferative state and decreases the final
tumor size. However, relatively speaking, the sim-
ulated tumor growth statistics are insensitive to k0
compared to the influences of the aforementioned
other factors. Note that even when the suppres-
sion factors can only turn the “transformed” cells
back into dormant cells and do not kill any “trans-
formed” cells (i.e. k0 = 0), a “switch” behavior
from a dormant state to a rapid proliferative state
can still emerge. This indicates that turning the ac-
tive proliferative cells back into dormant cells could
also be a possible independent mechanism leading
to a dormancy period and a subsequent “switch” to
a proliferative state.
Figure 6. (Color online) Tumor area AT
normalized by the area A0 of the growth
permitting region of a simulated noninvasive
tumor growing in the ECM under different killing
rates by microenvironmental suppression factors.
The parameter k0 is the fraction that the
suppression factors from the microenvironment kill
the actively dividing proliferative cells when the
suppression factors counteract these cells.
Discussion
In this paper, we generalized a two-dimensional cel-
lular automaton (CA) model previously developed
for proliferative growth of avascular solid tumors to
investigate tumor dormancy and evasion from dor-
mancy to proliferation. Our CA dormancy model
incorporates a variety of cell-level tumor-host in-
teractions, including those between the tumor and
the suppression factors in the microenvironment,
for example the immune system. Our CA dor-
mancy model induces a “competition” between the
tumor’s propensity to proliferate and the microen-
vironmental factors that suppress its growth. Our
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CA dormancy model predicts a dramatic emergent
“switch” behavior from a dormant state to a rapidly
proliferative state. Our results show that under the
suppression of microenvironmental factors, the tu-
mor develops a highly aspherical morphology with
an larger proliferative region and a smaller necrotic
region than those of a tumor that grows without
the presence of suppression factors. We also pre-
dict that if the number of actively dividing cells
within the proliferative rim of tumor reaches a crit-
ical, yet low level, the tumor has a large probability
to resume rapid regrowth and exit dormancy. In
addition, we demonstrate that a variety of different
factors could greatly alter tumor growth dynamics,
including the rate of phenotypic transformations,
the suppression rate by the microenvironmental fac-
tors, the mechanical rigidity of the microenviron-
ment, and the strength of the suppression factors.
However, relatively speaking, the tumor growth is
insensitive to the strength of the suppression fac-
tors in terms of killing active proliferative cells. We
inferred from our simulation results a qualitative
phase diagram to characterize the growth dynam-
ics of the tumor under the suppression of microenvi-
ronmental factors in terms of the phenotypic trans-
formation rate and the suppression rate. In this
paper we focused on the two-dimensional case, but
our model should be easily generalized to three di-
mensions.
At the cellular level, the origin of the “stalemate”
between the tumor and microenvironmental sup-
pression factors remains unclear. This “stalemate”
may come from cell proliferation balanced by cell
death, which could be the case for a dividing can-
cer stem cell [52]. Arrested tumor cell proliferation
imposed by microenvironmental factors could also
result in the “stalemate” between the tumor and
the microenvironmental suppression factors. Both
scenarios could account for the case of differenti-
ated cancer cells, since our CA dormancy model is
coarse-grained and therefore considers the effective
behavior of the tumor.
Our CA dormancy model may shed light on
the fundamental understanding of cancer dormancy
phenomenon. Specifically, our CA dormancy model
proposes possible scenarios for cancer dormancy
that during the dormancy period the great major-
ity of proliferative cells stay in a dormant state,
while only a small portion of proliferative cells, i.e.,
“transformed” cells are actively dividing, and the
microenvironmental suppression factors counteract
these “transformed” cells by either killing them or
turning them back into dormant cells. As a result,
the tumor cell population is barely expanding dur-
ing the dormancy period. It is noteworthy that our
CA dormancy model predicts that the tumor ei-
ther eventually spontaneously emerges or is eradi-
cated after a period of a “stalemate” between the
tumor and the microenvironmental suppression fac-
tors; or the tumor is eradicated before such a “stale-
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mate” could ever develop. These predicted scenar-
ios arising from the interaction between the tumor
and the microenvironmental suppression factors in
our simulation qualitatively match the experimen-
tal observations of the cancer immunoediting pro-
cess, by which the immune system controls the tu-
mor growth and necessarily leads to tumor escape
or elimination [53]. The predictions of our CA dor-
mancy model can be further verified by comparing
the macroscopic geometrical and dynamical prop-
erties of our simulated tumor in different microen-
vironments [54] to those obtained by experimental
data from future animal studies. In future work
we plan on incorporating recently discovered mech-
anisms for cancer dormancy via the clinical trials
and experiments [55, 56] to better inform our com-
putational model. These results together could aid
in answering the important fundamental question of
whether the majority of cancer cells in a dormant
tumor are arrested at a certain stage of the cell cy-
cle or not. Furthermore, they will have significant
treatment implications in terms of what stage of the
cell cycle the therapies should target [57].
Besides the aforementioned influences, our find-
ings informed by clinical data might be able to pro-
vide further insights to novel early cancer detection
and therapy. For example, a new cancer drug that
suppresses the emission of CD47 by the tumor tis-
sues, which helps the tumor cells evade attack by
the immune system, has been discovered [58]. It was
shown via in vitro experiments that this drug is able
to kill a variety of cancer cell types. Thus, an effec-
tive clinical application of this drug depends upon
the ability to identify different tumor cell popula-
tions while they are dormant. Our work may serve
to provide insights to the application of this new
drug as well by contributing to the development of
new early detection methods. In addition, our work
may shed light on why the immune system may
not always be able to prevent tumor progression.
Specifically, our work shows that even if the immune
system maintains its strength throughout the tumor
growth process, there is still a high possibility that
the immune system could eventually fail, which is
to be contrasted with the simple explanations that
it becomes weaker as the tumor develops [15–18].
Also, for a tumor of a specific type, we can extract
the parameter values in our model by fitting our
simulation results to the statistics of a real in-vitro
or in-vivo tumor of this type. Then we can utilize
our model to explore optimal treatment strategies
for the tumors of this specific type. In addition,
once we determine the effects of a specific microen-
vironmental factor (e.g., specific integrins [59]) on
the parameter values in our model, we could then
study the effects of this microenvironmental factor
on the tumor growth dynamics.
Our current CA dormancy model is still prelim-
inary, and to achieve our ultimate goal of under-
standing cancer dormancy and progression, we need
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to develop robust models that incorporate appro-
priate cell-level tumor-host interactions that are in-
formed by experiments. For example, by explic-
itly considering angiogenesis and using more real-
istic distribution of “transformed” tumor cells’ re-
sistance to microenvironmental suppression factors
(currently we just divide the “transformed” cells
into two types with respect to their resistance to
microenvironmental suppression factors: weak and
strong), our model might be able to yield more
realistic results and improve our understanding of
cancer dormancy and progression. Also, the effects
of tumor cell competition, cooperation and the mi-
croenvironmental changes caused by tumor cell ac-
tivities could be incorporated to further strengthen
our CA dormancy model [60]. It is noteworthy that
although we employ interaction rules based on a dis-
crete cell model to describe “competition” between
the tumor and the microenvironmental suppression
factors, alternatives such as evolutionary game the-
ory implemented by partial-differential equations
are also available to address the interplay between
the tumor and the microenvironment [61].
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